Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Biogen (NASDAQ:BIIB) had its target price boosted by investment analysts at Needham & Company LLC from $256.00 to $290.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC‘s price objective suggests a potential upside of 18.83% from the stock’s previous close.

BIIB has been the topic of a number of other reports. Wedbush increased their price objective on shares of Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, July 30th. UBS Group upped their price target on Biogen from $240.00 to $270.00 and gave the company a “buy” rating in a report on Friday, October 9th. HSBC increased their price target on shares of Biogen from $165.00 to $175.00 and gave the company a “reduce” rating in a research note on Thursday, September 10th. JPMorgan Chase & Co. raised shares of Biogen from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $210.00 to $300.00 in a report on Monday, October 12th. Finally, Weiss Ratings upgraded shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $245.61.

Biogen Price Performance

Biogen stock opened at $244.05 on Thursday. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen has a 52-week low of $138.00 and a 52-week high of $258.78. The firm has a market cap of $36.06 billion, a PE ratio of 43.19, a price-to-earnings-growth ratio of 2.99 and a beta of 0.09. The company’s 50 day moving average is $225.73 and its two-hundred day moving average is $200.39.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.63. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. During the same quarter in the prior year, the business earned $4.81 EPS. Biogen’s revenue was up 10.6% on a year-over-year basis. On average, research analysts expect that Biogen will post 12.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BIIB. BlackRock Inc. purchased a new position in shares of Biogen during the second quarter worth approximately $3,453,878,000. Primecap Management Co. CA acquired a new position in shares of Biogen in the 2nd quarter valued at $3,274,304,000. Wellington Management Group LLP raised its position in Biogen by 5.3% in the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock valued at $673,560,000 after purchasing an additional 155,828 shares during the last quarter. Amundi raised its position in Biogen by 91.8% in the 2nd quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock valued at $327,727,000 after purchasing an additional 726,004 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in Biogen during the 2nd quarter worth $322,640,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q3 results exceeded expectations: Biogen reported adjusted EPS of $2.62 versus the roughly $2.00 consensus estimate, while revenue rose 10.6% year over year to $2.80 billion, above forecasts near $2.63 billion. BIIB’s Q3 Earnings Beat, New Drugs Aid Sales
• Positive Sentiment: Newer products are driving the turnaround: Growth-portfolio revenue jumped 49% to $1.26 billion, representing 63% of core pharmaceutical sales. Rare-disease revenue increased 27% to $676 million, helped by the first full quarter of contributions from Apellis products acquired in May. Biogen Q3 Revenue Rises 11%
• Positive Sentiment: 2026 guidance improved: Biogen raised the lower end of its full-year reported non-GAAP diluted EPS outlook to $12.20, while maintaining a range of $12.20 to $13.00. Management characterized the business as having returned to growth. Biogen Has Returned To Growth
• Positive Sentiment: Some analysts see additional upside: Baird raised its price target to $290, supporting the view that Biogen’s growth portfolio can offset erosion in its older multiple-sclerosis franchise. Baird Raises Biogen Price Target
• Neutral Sentiment: Headline profitability was weaker: Biogen posted a GAAP net loss of $20.6 million, or $0.14 per share, compared with $466.5 million of net income a year earlier. The loss primarily reflected $284 million in acquired in-process research and development, upfront and milestone expenses tied largely to the RayThera acquisition. Biogen Swings to Loss
• Negative Sentiment: Valuation and positioning could limit gains: Barclays raised its target to $230 but retained an “equal weight” rating, implying downside from the recent share level. Unusually heavy put-option activity also signals increased short-term hedging or bearish speculation. Barclays Biogen Ratings

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.